The Indian market snapped a 5-day winning streak to close in the red on Friday, tracking muted global cues.The S&P BSE Sensex fell by more than 800 points, while the Nifty50 closed below the 25,000 level. Market Summary

Technical Breakout Stocks: How to trade Zomato, Gillette India, and Granules India on Monday - Market Summary

Indian markets closed in the green for the fourth consecutive day in a row on Wednesday tracking positive global cues.The S&P BSE Sensex rose nearly 300 points while the Nifty50 closed above 24,950 levels. Market Summary

Technical Breakout Stocks: How to trade Torrent Power, Suven Pharma and Granules India on Thursday - Market Summary

KFin Technologies Ltd, Aptech Ltd, Granules India Ltd and NCC Ltd are among the other gainers in the BSE’s ‘A’ group today, 31 July 2024.

Torrent Power Ltd leads gainers in ‘A’ group

Will Oncology Be A Game Changer For Granules India In FY26? MD Krishna Chigurupati Shares

​On July 30, the closing prices of five stocks from the Nifty500 pack rallied over 1.5% relative to the VWAP, and a shift above the VWAP suggests a potential bullish trend, according to

Granules India and 5 other stocks closed above VWAP

Here are a few stocks likely to be in focus on Wednesday, 31 July:

Stocks to watch: Tata Consumer, ITC, Tata Steel, IOC, Torrent Power, Titagarh Rail, Granules India | Stock Market News

Granules India on Tuesday said its profit after tax rose nearly three-fold year-on-year to Rs 135 crore for the first quarter ended June 30, 2024.

Granules India PAT surges to Rs 135 cr in June quarter

Granules India’s Q1 net profit triples to ₹134.64 crore, revenue up 20%, driven by formulation growth and North America business.

Granules Q1 net surges to ₹135 cr., revenue rises 20%

Granules India reports 181% increase in net profit, driven by revenue growth and improved PAT margin.

Granules India’s Q1 net up 181 per cent at ₹134 crore

Granules India rallied 3.37% to Rs 583.40 after the pharma company reported a consolidated net profit of Rs 134.65 crore in Q1 FY25, steeply higher than Rs 47.89 crore posted in Q1 FY24.

Granules India hits life high as PAT soars to Rs 135 cr in Q1 FY25

Granules India consolidated net profit rises 181.11% in the June 2024 quarter

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Granules India Limited is a pharmaceutical company that manufactures finished dosages (FDs), pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs).